The scientific article discussed: Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomized, double-blind, placebo-controlled, phase 3 trial https://bit.ly/3L6LKCC
IFFGD is a nonprofit education and research organization. Our mission is to inform, assist, and support people affected by gastrointestinal disorders.
Our original content is authored specifically for IFFGD readers, in response to your questions and concerns.
If you found this article helpful, please consider supporting IFFGD with a small tax-deductible donation.
How to get Beyond Better to Feeling your Best Welcome to “Beyond Better ” This series was created to assist you in effectively communicating with
How to get Beyond Better to Feeling your Best Welcome to “Beyond Better ” This series was created to assist you in effectively communicating with
How to get Beyond Better to Feeling your Best Welcome to “Beyond Better ” This series was created to assist you in effectively communicating with
Cannabinoid Hyperemesis Syndrome (CHS) In this episode of 5 Minutes in GI, we sit down with Dr. Thangam Venkatesan and Dr. Benjamin Liu to discuss
Cannabinoid Hyperemesis Syndrome (CHS) In this episode of 5 Minutes in GI, we sit down with Dr. Thangam Venkatesan and Dr. Benjamin Liu to discuss
In this episode of 5 Minutes in GI, we welcome back Dr. Saam Dilmaghani, a resident physician at the Mayo Clinic. He discusses foods that
This information is in no way intended to replace the guidance of your doctor.
We advise seeing a physician whenever a health problem arises requiring an expert’s care.
© Copyright 2025 International Foundation for Gastrointestinal Disorders, Inc. (IFFGD).
All Rights Reserved.
Keep up-to-date on the latest news, stories, tips, research highlights, and more!
